Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Morgan Sindall to beat 2025 guidance after strong first half

(Sharecast News) - Building, fit-out and construction services group Morgan Sindall has revealed that full-year results for 2025 will be "significantly ahead" of previous expectations. The company said that, since its last update in May, strong trading activity in the Fit Out division has continued, providing increased visibility for the rest of the year.

As a result, operating profits from this division are now expected to beat previous guidance of £60m-86m. This was the second time that Morgan Sindall has raised predictions for the Fit Out unit, having hiked the target range from £50m-70m at its full-year results in February.

Meanwhile, in the construction division, profits and revenues are now expected to be ahead of previous expectations.

The rest of the business continues to trade in line with forecasts, though group profit before tax should now be significantly ahead of market estimates.

The company had said in March that 2025 adjusted pre-tax profits would be slightly ahead of the £178m consensus estimate at the time, compared with £172.5m earned in 2024.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.